Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive symbols : Virx save search
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
VIRX | $0.8367 -1.31% -1.33% 55K
|
Manufacturing
|
| O: -12.71%
H: 0.97%
C: -24.27%
t-cell positive topline trial therapeutics results
Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors
Published: 2022-01-31 (Crawled : 14:00) - biospace.com/
VIRX | $0.8367 -1.31% -1.33% 55K
|
Manufacturing
|
| O: 0.0%
H: 13.69%
C: 11.2%
solid tumors phase 1b trial therapeutics phase 1 positive phase 2b
Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021
Published: 2021-12-13 (Crawled : 20:00) - biospace.com/
VIRX | $0.8367 -1.31% -1.33% 55K
|
Manufacturing
|
| O: -2.86%
H: 0.0%
C: 0.0%
phase 1b therapeutics presentation phase 1 positive phase 2b
Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral Combination of Nanatinostat and Valganciclovir (Nana-val) for the Treatment of Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma
Published: 2021-11-29 (Crawled : 14:00) - biospace.com/
VIRX | $0.8367 -1.31% -1.33% 55K
|
Manufacturing
|
| O: 3.57%
H: 4.21%
C: -12.45%
treatment fda drug granted therapeutics orphan drug positive t-cell designation
Viracta Therapeutics Initiates Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors
Published: 2021-10-06 (Crawled : 12:15) - prnewswire.com
VIRX | $0.8367 -1.31% -1.33% 55K
|
Manufacturing
|
| O: -1.69%
H: 3.18%
C: 0.27%
solid tumors phase 1 positive trial phase 1b phase 2b
Viracta Therapeutics Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors
Published: 2021-07-21 (Crawled : 14:00) - biospace.com/
VIRX | $0.8367 -1.31% -1.33% 55K
|
Manufacturing
|
| O: 1.34%
H: 2.64%
C: 0.26%
fda clearance fda solid tumors phase 1 positive trial phase 1b clearance phase 2b
Viracta Therapeutics Announces the Initiation of NAVAL-1, a Global Pivotal Trial for the Treatment of Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma
Published: 2021-06-01 (Crawled : 14:00) - biospace.com/
VIRX | $0.8367 -1.31% -1.33% 55K
|
Manufacturing
|
| O: -3.66%
H: 6.3%
C: -0.9%
treatment positive trial
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.